Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

被引：29

作者：

Wilson, Stuart C. ^{[1
]}

Atrash, Butrus ^{[1
]}

Barlow, Clare ^{[1
]}

Eccles, Susan ^{[1
]}

Fischer, Peter M. ^{[2
]}

Hayes, Angela ^{[1
]}

Kelland, Lloyd ^{[1
]}

Jackson, Wayne ^{[2
]}

Jarman, Michael ^{[1
]}

Mirza, Amin ^{[1
]}

Moreno, Javier ^{[1
]}

Nutley, Bernard P. ^{[1
]}

Raynaud, Florence I. ^{[1
]}

Sheldrake, Peter ^{[1
]}

Walton, Mike ^{[1
]}

Westwood, Robert ^{[2
]}

Whittaker, Steven ^{[1
]}

Workman, Paul ^{[1
]}

McDonald, Edward ^{[1
]}

机构：

[1] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, Sutton SM2 5NG, Surrey, England

[2] Cyclacel Ltd, Dundee DD1 5JJ, Scotland

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2011年 / 19卷 / 22期

关键词：

Cyclin; Kinase; Inhibitor; Purine; CDK; CYCLIN-DEPENDENT KINASES; X-RAY CRYSTALLOGRAPHY; CYC202; R-ROSCOVITINE; CELL-CYCLE; SELICICLIB CYC202; CANCER-TREATMENT; USEFUL TARGETS; IN-VITRO; EXPRESSION; LESSONS;

D O I：

10.1016/j.bmc.2011.08.051

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound alpha SbR-21 inhibits CDK2/cyclin E with IC(50) = 30 nM, CDK7-cyclin H with IC(50) = 1.3 mu M, and CDK9-cyclinT with IC(50) = 0.11 mu M; it (CCT68127) inhibits growth of HCT116 colon cancer cells in vitro with GI(50) = 0.7 mu M; and shows antitumour activity when dosed p.o. at 50 mg/kg to mice bearing HCT116 solid human tumour xenografts. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：6949 / 6965

页数：17

共 46 条

[1]

Aleem E, 2004, CELL CYCLE, V3, P35

[2] Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors [J].

Anderson, Malcolm ;

Andrews, David M. ;

Barker, Andy J. ;

Brassington, Claire A. ;

Breed, Jason ;

Byth, Kate F. ;

Culshaw, Janet D. ;

Finlay, M. Raymond V. ;

Fisher, Eric ;

McMiken, Helen H. J. ;

Green, Clive P. ;

Heaton, Dave W. ;

Nash, Ian A. ;

Newcombe, Nicholas J. ;

Oakes, Sandra E. ;

Pauptit, Richard A. ;

Roberts, Andrew ;

Stanway, Judith J. ;

Thomas, Andrew P. ;

Tucker, Julie A. ;

Walker, Mike ;

Weir, Hazel M. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) :5487-5492

[3]

BACH S, 2007, INHIB CYCLIN DEPEND, P103

[4] Inhibition of cyclin-dependent kinases - A review of the recent patent literature [J].

Basso, Andrea D. ;

Doll, Ronald J. .

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2006, 1 (03) :357-367

[5] A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days [J].

Benson, C. ;

White, J. ;

De Bono, J. ;

O'Donnell, A. ;

Raynaud, F. ;

Cruickshank, C. ;

McGrath, H. ;

Walton, M. ;

Workman, P. ;

Kaye, S. ;

Cassidy, J. ;

Gianella-Borradori, A. ;

Judson, I. ;

Twelves, C. .

BRITISH JOURNAL OF CANCER, 2007, 96 (01) :29-37

[6] Clinical anticancer drug development: targeting the cyclin-dependent kinases [J].

Benson, C ;

Kaye, S ;

Workman, P ;

Garrett, M ;

Walton, M ;

de Bono, J .

BRITISH JOURNAL OF CANCER, 2005, 92 (01) :7-12

[7] Evaluation of the first cytostatically active 1-aza-9-oxafluorenes as novel selective CDK1 inhibitors with P-glycoprotein modulating properties [J].

Brachwitz, K ;

Voigt, B ;

Meijer, L ;

Lozach, P ;

Schächtele, C ;

Molnár, J ;

Hilgeroth, A .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (05) :876-879

[8] Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine [J].

DeAzevedo, WF ;

Leclerc, S ;

Meijer, L ;

Havlicek, L ;

Strnad, M ;

Kim, SH .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2) :518-526

[9]

Fischer PM, 2008, CANCER DRUG DESIGN AND DISCOVERY, P253, DOI 10.1016/B978-012369448-5.50014-8

[10]

Fischer PM, 2004, CELL CYCLE, V3, P742

← 1 2 3 4 5 →